References
- Stewart S, Ekman I, Ekman T, Oden A, Rosengren A. Population impact of heart failure and the most common forms of cancer: a study of 1 162 309 hospital cases in Sweden (1988 to 2004). Circ Cardiovasc Qual Outcomes. 2010 Nov; 3( 6): 573– 80.
- Jhund PS, Macintyre K, Simpson CR, Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation. 2009 Feb 3; 119( 4): 515– 23.
- Castagno D, Baird-Gunning J, Jhund PS, Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. Am Heart J. 2011 Nov; 162( 5): 938– 48. e2.
- Neubauer S. High-energy phosphate metabolism in normal, hypertrophied and failing human myocardium. Heart Fail Rev. 1999 Oct; 4( 3): 269– 80.
- Gupte AA, Hamilton DJ, Cordero-Reyes AM, Mechanical unloading promotes myocardial energy recovery in human heart failure. Circ Cardiovasc Genet. 2014 Jun; 7( 3): 266– 76.
-
Bedi
KC
Jr , Snyder NW, Brandimarto J, Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure. Circulation. 2016 Feb 23; 133( 8): 706– 16. - Riggs K, Ali H, Taegtmeyer H, Gutierrez AD. The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure. Metab Syndr Relat Disord. 2015 Sep; 13( 7): 292– 7.
- Ferrannini E DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J. 2015 Sep 7; 36( 34): 2288– 96.
- Filion KB Suissa S. DPP-4 Inhibitors and Heart Failure: Some Reassurance, Some Uncertainty. Diabetes Care. 2016 May; 39( 5): 735– 7.
- Ou HT, Chang KC, Li CY, Wu JS. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study. Cardiovasc Diabetol. 2016 Mar 1; 15: 41.
- Thohan V, Stetson SJ, Nagueh SF, Cellular and hemodynamics responses of failing myocardium to continuous flow mechanical circulatory support using the DeBakey-Noon left ventricular assist device: a comparative analysis with pulsatile-type devices. J Heart Lung Transplant. 2005 May; 24( 5): 566– 75.
- Cordero-Reyes AM, Gupte AA, Youker KA, Freshly isolated mitochondria from failing human hearts exhibit preserved respiratory function. J Mol Cell Cardiol. 2014 Mar; 68: 98– 105.
- Hamirani YS, Kundu BK, Zhong M, Noninvasive Detection of Early Metabolic Left Ventricular Remodeling in Systemic Hypertension. Cardiology. 2016; 133( 3): 157– 62.
- Gupte AA Hamilton DJ. Molecular Imaging and Precision Medicine. Cardiology. 2016; 133( 3): 178– 80.
- Grieve DJ, Cassidy RS, Green BD. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol. 2009 Aug; 157( 8): 1340– 51.
- Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008; 117( 18): 2340– 50.
- Hansen J, Brock B, Botker HE, Gjedde A, Rungby J, Gejl M. Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited. Rev Endocr Metab Disord. 2014 Sep; 15( 3): 219– 31.
- Bhashyam S, Fields AV, Patterson B, Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy. Circ Heart Fail. 2010 Jul; 3( 4): 512– 21.
- Aravindhan K, Bao W, Harpel MR, Willette RN, Lepore JJ, Jucker BM. Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart. PLoS One. 2015 Jun 22; 10( 6): e0130894.
- Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28; 375( 4): 311– 22.
- Kashiwagi Y, Nagoshi T, Yoshino T, Expression of SGLT1 in Human Hearts and Impairment of Cardiac Glucose Uptake by Phlorizin during Ischemia-Reperfusion Injury in Mice. PLoS One. 2015; 10( 6): e0130605.
- Kurosaki E Ogasawara H. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. Pharmacol Ther. 2013 Jul; 139( 1): 51– 9.
- Zinman B, Wanner C, Lachin JM, Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26; 373( 22): 2117– 28.
- Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA. SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. Diabetes Care. 2016 May; 39( 5): 717– 25.
- Singh JS, Fathi A, Vickneson K, Research into the effect of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. Cardiovasc Diabetol. 2016; 15: 97.
- Mudaliar S, Alloju S, Henry RR. Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis. Diabetes Care. 2016 Jul; 39( 7): 1115– 22.
- Lopatin YM, Rosano GM, Fragasso G, Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. Int J Cardiol. 2016 Jan 15; 203: 909– 15.
- Lee L, Campbell R, Scheuermann-Freestone M, Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation. 2005 Nov 22; 112( 21): 3280– 8.
- Aldakkak M, Camara AK, Heisner JS, Yang M, Stowe DF. Ranolazine reduces Ca2+ overload and oxidative stress and improves mitochondrial integrity to protect against ischemia reperfusion injury in isolated hearts. Pharmacol Res. 2011 Oct; 64( 4): 381– 92.
- Brown DA, Hale SL, Baines CP, Reduction of early reperfusion injury with the mitochondria-targeting peptide bendavia. J Cardiovasc Pharmacol Ther. 2014 Jan; 19( 1): 121– 32.
- Birk AV, Chao WM, Bracken C, Warren JD, Szeto HH. Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. Br J Pharmacol. 2014 Apr; 171( 8): 2017– 28.
DOI: https://doi.org/10.14797/mdcj-13-1-25 | Journal eISSN: 1947-6108
Language: English
Page range: 25 - 28
Published on: Jan 1, 2017
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2017 Dale J. Hamilton, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.